Tu1047 Assessing Key Barriers to Treatment of Chronic Hepatitis C Virus (HCV) With Next Generation Agents in a Veteran Population

variability was noted in the responses, with some waiting as long as 5 years to repeat screening in the presence of a high-risk adenoma with IBP. Awareness of MSTF recommendations or adherence to these guidelines still remains weak among GI physicians and physician-extenders. Publicity of guidelines and further data to support their recommendations are warranted. REFERENCES 1.Lebwohl B, et al. Gastrointest Endosc 2011;73(6):1207-1214. 2.Neerincx M, et al. Endoscopy 2010;42(9):730-735. 3.Lieberman DA, et al. Gastroenterology 2012;143(3):844-57.